US life sciences damages averaged $33.5m between 2019-2025

Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

Kirkland clears conflicts hurdle in trade secrets spat

7 August 2026 A federal judge has refused to disqualify Kirkland & Ellis from representing a healthcare tech company after a conflict check came under scrutiny.

Regulation & Industry

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

5 August 2026 From advising pioneering startups to championing women in the profession, Fran Salisbury of Mewburn Ellis has spent her career making innovation count. Here, she reflects on the challenges, opportunities and motivations that continue to drive her.

Regulation & Industry

Where Big Pharma is betting big in the M&A boom

29 July 2026 Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?

More features

Kirkland clears conflicts hurdle in trade secrets spat

Former senior attorney-advisor to ITC commissioners joins Mintz

The UPC plugs another gap in its procedural rulebook

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers

Brown Rudnick lands largest lateral IP team hire in firm history

Fran Salisbury: ‘There’s nothing quite like finding the missing piece’

K&L Gates expands European practice with Munich team hire

Patent litigator joins Baker Botts in London as UPC grows in significance

US life sciences damages averaged $33.5m between 2019-2025

More on this story

Editor's picks

Editor's picks

More features